ROC 101
Alternative Names: ROC-101Latest Information Update: 11 Nov 2025
At a glance
- Originator Sanofi
- Developer AllRock Bio
- Class Anti-inflammatories; Antifibrotics; Antihypertensives; Small molecules
- Mechanism of Action Rho-associated kinase inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Pulmonary arterial hypertension
- Phase I Interstitial lung diseases
Most Recent Events
- 29 Oct 2025 Phase-II clinical trials in Pulmonary arterial hypertension in USA (PO) (NCT07175038)
- 29 Sep 2025 AllRock Bio plans a phase IIa ROCSTAR trial for Pulmonary arterial hypertension and Interstitial lung disease in late 2025 (NCT07175038)
- 16 Sep 2025 Phase-I clinical trials in Interstitial lung diseases (In volunteers) in USA (PO) before September 2025 (AllRock Bio pipeline, September 2025)